BRISTOL-MYERS SQUIBB COMPANY

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$152.8M

Filings

330

Firms Hired

Active Period

1999–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$7,530,000	12	4
2025	$10,080,000	14	4
2024	$5,280,000	12	3
2023	$8,880,000	13	3
2022	$5,400,000	9	2
2021	$6,140,000	9	2
2020	$10,240,000	11	2
2019	$4,100,000	8	2
2018	$3,830,000	8	2
2017	$3,610,000	8	2
2016	$2,840,000	8	2
2015	$3,580,000	9	2
2014	$2,745,000	9	2
2013	$2,836,000	12	3
2012	$5,520,000	19	4
2011	$4,160,000	17	4
2010	$4,506,000	19	4
2009	$4,289,276	19	4
2008	$4,375,520	24	6
2007	$10,980,000	15	7
2006	$5,740,000	12	7
2005	$5,040,000	15	6
2004	$2,720,000	10	5
2003	$5,320,000	8	4
2002	$7,320,000	8	4
2001	$7,260,000	8	4
2000	$6,880,000	9	4
1999	$1,600,000	5	4

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BRISTOL-MYERS SQUIBB COMPANY	$152,801,796	113
SQUIRE PATTON BOGGS	—	52
THE NICKLES GROUP, LLC	—	65
TODD STRATEGY GROUP	—	17
RICHARD F. HOHLT	—	33
THE GORLIN GROUP	—	19
WILLIAMS AND JENSEN, PLLC	—	8
DLA PIPER LLP (US)	—	11
GOLINHARRIS	—	6
MILLER STRATEGIES, LLC	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	289
SENATE	288
U.S. Trade Representative (USTR)	76
Commerce, Dept of (DOC)	73
Health & Human Services, Dept of (HHS)	67
Centers For Medicare and Medicaid Services (CMS)	61
Health Resources & Services Administration (HRSA)	41
State, Dept of (DOS)	31
Treasury, Dept of	21
Agriculture, Dept of (USDA)	15
Executive Office of the President (EOP)	5
Food & Drug Administration (FDA)	5
Environmental Protection Agency (EPA)	4
U.S. Agency for International Development (USAID)	4
White House Office	4
Office of Management & Budget (OMB)	2
Office of the Vice President of the United States	2
UNDETERMINED	2
Patent & Trademark Office (PTO)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	256
Medicare/Medicaid	Medicare/Medicaid	251
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	176
Budget/Appropriations	Budget/Appropriations	132
Copyright/Patent/Trademark	Copyright/Patent/Trademark	118
Trade (domestic/foreign)	Trade (domestic/foreign)	111
Pharmacy	Pharmacy	42
Agriculture	Agriculture	33
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	24
Government Issues	Government Issues	19
Clean Air and Water (quality)	Clean Air and Water (quality)	17
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	15
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	14
Foreign Relations	Foreign Relations	14
Insurance	Insurance	10
Economics/Economic Development	Economics/Economic Development	9
Advertising	Advertising	9
Environment/Superfund	Environment/Superfund	9
Telecommunications	Telecommunications	7
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	6

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: BRISTOL-MYERS SQUIBB COMPANY